Pacific Biosciences of California (PACB)

NASDAQ
5.39
-0.35(-6.10%)
After Hours
5.39
0.00(0.00%)
- Real-time Data
  • Volume:
    9,271,992
  • Day's Range:
    5.36 - 5.70
  • 52 wk Range:
    4.51 - 36.36

PACB Overview

Prev. Close
5.74
Day's Range
5.36-5.7
Revenue
134.69M
Open
5.61
52 wk Range
4.51-36.36
EPS
-0.81
Volume
9,271,992
Market Cap
1.22B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
6,050,217
P/E Ratio
-
Beta
1.44
1-Year Change
-77.55%
Shares Outstanding
224,383,347
Next Earnings Date
Aug 03, 2022
What is your sentiment on Pacific Biosciences?
or
Market is currently closed. Voting is open during market hours.

Pacific Biosciences of California News

Pacific Biosciences of California Analysis

Pacific Biosciences of California Company Profile

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio’s Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • 25 USD by the end of the year
    0
    • I need 44 for breakeven
      0
  • 10$ is undervalued imho. Great entry price.
    0
    • if $10 is undervalued, then how is $8.34?
      0
    • I taught 44 was undervalued
      0
  • why feb earnings is not released?
    0
    • Addet at 11,20 long
      0
      • 10 months ago Morgan Stanley raised price target to 45. This was the sell signale.
        0
        • 120.000 new shares for employees(80k+40k rsu). The 80k will be sold on monday instantly.
          0
      • It's a growth stock with ascensing revenues. Nothing else matters
        0
        • NASDAQ:PACB): Q3 Non-GAAP EPS of -$0.23 beats by $0.01; GAAP EPS of $0.08 beats by $0.30.Revenue of $34.89M
          0
          • not so fantastic, maybe encourages the shorters tomorrow. Alltough technically it's bullish and the whole smallcap sector gains this week. We'll see.
            0
        • ark Invest just bought a lot 250000 shares this week .go Cathy
          0
          • 88i
            0
          • it's a bad sign!
            0
        • "Oh, think twice... it's just another -10% for you and me in paradise!"
          0
          • Adding more at sub 30. This is the stock will make me a millionaire in coming years
            1
            • Mega RIP
              0